[ad_1] SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ — On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as “Chipscreen Biosciences”) and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the “Drug Clinical Trial Approval […]

[ad_1] SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ — On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company’s Investigational New Drug (IND) application for CS231295 tablets, a Class 1 […]